Calcitriol in combination therapy for prostate cancer: Pharmacokinetic and pharmacodynamic interactions

Journal of Cancer

Volumn 7, Issue 4, 2016, Pages 391-407

  Ben Eltriki, Mohamed ^a,b   Deb, Subrata ^c   Tomlinson Guns, Emma S ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ROOSEVELT UNIVERSITY   (United States)

Author keywords

Calcitriol; CYP enzymes; Metabolism; Pharmacodynamics; Pharmacokinetics; Prostate cancer; Vitamin D receptor

Indexed keywords

AR PROTEIN; CALCITRIOL; COLECALCIFEROL 24 HYDROXYLASE; CYTOCHROME P 450 27B1; CYTOCHROME P450; CYTOCHROME P450 3A4; PROTEIN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

CANCER CHEMOTHERAPY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PROSTATE CANCER; REVIEW;

EID: 84971552304     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.13470     Document Type: Review

References (134)

1. Jones G. Extrarenal vitamin D activation and interactions between vitamin D(2), vitamin D(3), and vitamin D analogs. Annu Rev Nutr. 2013;33:23-44.
2. Mawer EB, Schaefer K, Lumb GA, Stanbury SW. The metabolism of isotopically labelled vitamin D3 in man: the influence of the state of vitamin D nutrition. Clin Sci. 1971;40(1):39-53.
3. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci. 2004;29(12):664-673.
4. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin. 2008;24(1):139-149.
5. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011;1814(1):186-199.
6. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(2):582S-586S.
7. Ross AC, Taylor CL, Yaktine AL, Del Valle HB. In: Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC). Institute of Medicine (2011)
8. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19(7):468-483.
9. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol. 2007;103(3-5):708-711.
10. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007;167(10):1050-1059.
11. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586-1591.
12. Trump DL, Chadha MK, Sunga AY, et al. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int. 2009;104(7):909-914.
13. Force UPST. Dietary Reference Intakes for Vitamin D and Calcium. 2012. (http://www.ahrq.gov/policymakers/case-studies/coe1301.html). Last accessed: Setpember 10, 2015.
14. Bikle DD. Vitamin D and cancer: the promise not yet fulfilled. Endocrine. Jan 9 2014.
15. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007;85(3):649-650.
16. Balvers MG, Brouwer-Brolsma EM, Endenburg S, de Groot LC, Kok FJ, Gunnewiek JK. Recommended intakes of vitamin D to optimise health, associated circulating 25-hydroxyvitamin D concentrations, and dosing regimens to treat deficiency: workshop report and overview of current literature. Journal of nutritional science. 2015;4:e23.
17. Morris HA, Anderson PH. Autocrine and paracrine actions of vitamin d. Clin Biochem Rev. 2010;31(4):129-138.
18. Demay MB. Mechanism of vitamin D receptor action. Ann N Y Acad Sci. 2006;1068:204-213.
19. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294(5548):1866-1870.
20. Haussler MR, Haussler CA, Bartik L, et al. Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev. 2008;66(10 Suppl 2):S98-112.
21. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000;5(1):173-179.
22. Chen TC, Holick MF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab. 2003;14(9):423-430.
23. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684-700.
24. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998;139(3):1197-1207.
25. Levine BS, Singer FR, Bryce GF, Mallon JP, Miller ON, Coburn JW. Pharmacokinetics and biologic effects of calcitriol in normal humans. J Lab Clin Med. 1985;105(2):239-246.
26. Fakih MG, Trump DL, Muindi JR, et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res. 2007;13(4):1216-1223.
27. Wagner D, Trudel D, Van der Kwast T, et al. Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab. 2013;98(4):1498-1507.
28. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.
29. Kachuri L, De P, Ellison LF, Semenciw R. Cancer incidence, mortality and survival trends in Canada, 1970-2007. Chronic Dis Inj Can. 2013;33(2):69-80.
30. Society CC. Prostate cancer statistics 2013.
31. Society CC. Canadian Cancer Statistics, percentage of all estimated cancer death in mens 2014.
32. Romero Otero J, Garcia Gomez B, Campos Juanatey F, Touijer KA. Prostate cancer biomarkers: An update. Urol Oncol. Feb 1 2014.
33. Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol. 2013;5(6):318-329.
34. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41(6):858-887.
35. SharifiN, Auchus RJ. Steroid biosynthesis and prostate cancer. Steroids. 2012;77(7):719-726.
36. Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol. 2005;23(32):8212-8218.
37. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol. 2007;25(5):413-419.
38. Zhong J, Ding L, Bohrer LR, et al. p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis. Cancer Res. 15 2014;74(6):1870-1880.
39. McMurtry J, Richards M, Brocht D. Serum corticosterone concentrations in developing shell-less and shelled turkey embryos. Comp Biochem Physiol A Comp Physiol. 1991;100(1):135-137.
40. Wu Y, Zhao W, Zhao J, et al. Identification of androgen response elements in the insulin-like growth factor I upstream promoter. Endocrinology. 2007;148(6):2984-2993.
41. Huang YW, Wang LS, Chang HL, et al. Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol. 2006;100(1-3):24-33.
42. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol. 2002;197(1-2):231-238.
43. van Dodewaard-de Jong JM, Verheul HM, Bloemendal HJ, de Klerk JM, Carducci MA, van den Eertwegh AJ. New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence? Clin Genitourin Cancer. Jan 21 2015.
44. Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha, 24-dihydroxyvitamin D2. Prostate. 2003;55(3):159-167.
45. Wolff JM. Chemotherapy in hormone-refractory prostate cancer. Front Radiat Ther Oncol. 2008;41:103-107.
46. Sartor O, Gillessen S. Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian J Androl. 2014;16(3):426-431.
47. Sigmon JR, Yentzer BA, Feldman SR. Calcitriol ointment: a review of a topical vitamin D analog for psoriasis. J Dermatolog Treat. 2009;20(4):208-212.
48. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1, 25-dihydroxyvitamin D3. Endocrinology. 1995;136(1):20-26.
49. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993;132(5):1952-1960.
50. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol. 2004;89-90(1-5):519-526.
51. Muindi JR, Yu WD, Ma Y, et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 2010;151(9):4301-4312.
52. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1, 25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 1999;5(6):1339-1345.
53. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159(6):2035-2039; discussion 2039-2040.
54. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int. 2008;101 Suppl 2:11-15.
55. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25(6):669-674.
56. Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;65(1):33-40.
57. Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1alpha, 25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology. 2004;66(1):62-66.
58. Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet. 1990;6(6):182-186.
59. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360(9340):1155-1162.
60. Chen TC, Sakaki T, Yamamoto K, Kittaka A. The roles of cytochrome P450 enzymes in prostate cancer development and treatment. Anticancer Res. 2012;32(1):291-298.
61. Deb S, Pandey M, Adomat H, Guns ES. Cytochrome P450 3A-mediated microsomal biotransformation of 1alpha, 25-dihydroxyvitamin D3 in mouse and human liver: drug-related induction and inhibition of catabolism. Drug Metab Dispos. 2012;40(5):907-918.
62. Deb S, Chin MY, Adomat H, Guns ES. Abiraterone inhibits 1alpha, 25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro. J Steroid Biochem Mol Biol. 2014;144 (Pt A):50-58.
63. Deb S, Chin MY, Adomat H, Guns ES. Ginsenoside-mediated blockade of 1alpha, 25-dihydroxyvitamin D inactivation in human liver and intestine in vitro. J Steroid Biochem Mol Biol. 2014;141:94-103.
64. Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephrourol Mon. 2013;5(3):792-800.
65. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol. 2003;170(6 Pt 1):2444-2452.
66. Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365(5):410-421.
67. Horvath HC, Lakatos P, Kosa JP, et al. The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 2010;58(3):277-285.
68. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 2004;160(9):825-841.
69. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(6 Suppl):1689S-1696S.
70. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. Human prostate cells synthesize 1, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 1998;7(5):391-395.
71. Whitlatch LW, Young MV, Schwartz GG, et al. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J Steroid Biochem Mol Biol. 2002;81(2):135-140.
72. Sakaki T, Sawada N, Takeyama K, Kato S, Inouye K. Enzymatic properties of mouse 25-hydroxyvitamin D3 1 alpha-hydroxylase expressed in Escherichia coli. Eur J Biochem. 1999;259(3):731-738.
73. Young MV, Schwartz GG, Wang L, et al. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis. 2004;25(6):967-971.
74. Swami S, Krishnan AV, Wang JY, et al. Dietary vitamin D(3) and 1, 25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology. 2012;153(6):2576-2587.
75. Sakaki T, Sawada N, Nonaka Y, Ohyama Y, Inouye K. Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 CYP24 can convert 1alpha, 25-dihydroxyvitamin D3 to calcitroic acid. Eur J Biochem. 1999;262(1):43-48.
76. St-Arnaud R. Targeted inactivation of vitamin D hydroxylases in mice. Bone. 1999;25(1):127-129.
77. Masuda S, Byford V, Arabian A, et al. Altered pharmacokinetics of 1alpha, 25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology. 2005;146(2):825-834.
78. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res. 1995;1(9):997-1003.
79. Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57(2):234-240.
80. Holt SK, Kwon EM, Koopmeiners JS, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010;70(13):1448-1460.
81. Ly LH, Zhao XY, Holloway L, Feldman D. Liarozole acts synergistically with 1alpha, 25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 1999;140(5):2071-2076.
82. Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS. Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1, 25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res. 2013;73(7):2289-2297.
83. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000;68(4):356-366.
84. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem. 2001;268(24):6346-6358.
85. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389-430.
86. Bieche I, Narjoz C, Asselah T, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics. 2007;17(9):731-742.
87. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 "pie". Drug Metab Dispos. 2006;34(5):880-886.
88. Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab. 2008;9(2):129-143.
89. Xu Y, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha, 25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006;69(1):56-65.
90. Gupta RP, He YA, Patrick KS, Halpert JR, Bell NH. CYP3A4 is a vitamin D-24-and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J Clin Endocrinol Metab. 2005;90(2):1210-1219.
91. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol. 1997;126(1):83-90.
92. Hendrickson WK, Flavin R, Kasperzyk JL, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011;29(17):2378-2385.
93. Chen L, Davey Smith G, Evans DM, et al. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2874-2881.
94. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170-1180.
95. Mun MJ, Kim TH, Hwang JY, Jang WC. Vitamin D receptor gene polymorphisms and the risk for female reproductive cancers: A meta-analysis. Maturitas. 2015;81(2):256-265.
96. Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29(9):3511-3536.
97. Gandini S, Gnagnarella P, Serrano D, Pasquali E, Raimondi S. Vitamin D receptor polymorphisms and cancer. Advances in experimental medicine and biology. 2014;810:69-105.
98. Ting HJ, Bao BY, Hsu CL, Lee YF. Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity. Endocrine. 2005;26(1):1-9.
99. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002;23(2):175-200.
100. Culig Z, Santer FR. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer. Steroids. 2013;78(9):851-859.
101. Uzoigwe J, Sauter ER. Cancer prevention and treatment using combination therapy with plant-and animal-derived compounds. Expert Rev Clin Pharmacol. 2012;5(6):701-709.
102. Gavrilov V, Steiner M, Shany S. The combined treatment of 1, 25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res. 2005;25(5):3425-3429.
103. Gavrilov V, Leibovich Y, Ariad S, Lavrenkov K, Shany S. A combined pretreatment of 1, 25-dihydroxyvitamin D3 and sodium valproate enhances the damaging effect of ionizing radiation on prostate cancer cells. J Steroid Biochem Mol Biol. 2010;121(1-2):391-394.
104. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res. 2001;7(4):1043-1051.
105. Ting HJ, Hsu J, Bao BY, Lee YF. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha, 25-dihydroxyvitamin D3. Cancer Lett. 2007;247(1):122-129.
106. Moffatt KA, Johannes WU, Miller GJ. 1Alpha, 25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 1999;5(3):695-703.
107. Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1, 25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol. 2002;168(2):756-761.
108. Watanabe S, Yamaguchi M, Sobue T, et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr. 1998;128(10):1710-1715.
109. Rao A, Woodruff RD, Wade WN, Kute TE, Cramer SD. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr. 2002;132(10):3191-3194.
110. Wang JY, Swami S, Krishnan AV, Feldman D. Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate. 2012;72(15):1628-1637.
111. Sha J, Pan J, Ping P, et al. Synergistic effect and mechanism of vitamin A and vitamin D on inducing apoptosis of prostate cancer cells. Mol Biol Rep. 2013;40(4):2763-2768.
112. Rashid SF, Moore JS, Walker E, et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha, 25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 2001;20(15):1860-1872.
113. Dunlap N, Schwartz GG, Eads D, et al. 1alpha, 25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha, 25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer. 18 2003;89(4):746-753.
114. Yee SW, Campbell MJ, Simons C. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol. 2006;98(4-5):228-235.
115. Beer TM. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int. 2005;96(4):508-513.
116. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112(2):326-330.
117. Shamseddine A, Farhat FS, Elias E, Khauli RB, Saleh A, Bulbul MA. High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. Urol Int. 2013;90(1):56-61.
118. Petrioli R, Pascucci A, Francini E, et al. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007;100(4):775-779.
119. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol. 2001;28(4 Suppl 15):49-55.
120. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21(1):123-128.
121. Flaig TW, Barqawi A, Miller G, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer. 2006;107(2):266-274.
122. Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol. 2004;27(5):535-541.
123. Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol. 2005;174(3):888-892.
124. Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1, 25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 2006;106(10):2136-2142.
125. Chadha MK, Tian L, Mashtare T, et al. Phase 2 trial of weekly intravenous 1, 25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer. 2010;116(9):2132-2139.
126. Morris MJ, Smaletz O, Solit D, et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004;100(9):1868-1875.
127. Holick MF. Vitamin D deficiency. N Engl J Med. Jul 19 2007;357(3):266-281.
128. Chan JS, Beer TM, Quinn DI, et al. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008;102(11):1601-1606.
129. Kimura M, Rabbani Z, Mouraviev V, et al. Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology. 2010;76(3):764 e714-720.
130. Wu W, Zanello L, Walker AM. S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death. Prostate. 2007;67(14):1498-1506.
131. Belochitski O, Ariad S, Shany S, Fridman V, Gavrilov V. Efficient dual treatment of the hormone-refractory prostate cancer cell line DU145 with cetuximab and 1, 25-dihydroxyvitamin D3. In Vivo. 2007;21(2):371-376.
132. Istfan NW, Person KS, Holick MF, Chen TC. 1alpha, 25-Dihydroxyvitamin D and fish oil synergistically inhibit G1/S-phase transition in prostate cancer cells. J Steroid Biochem Mol Biol. 2007;103(3-5):726-730.
133. Srinivas S, Feldman D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009;29(9):3605-3610.
134. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29(16):2191-2198.